399: OUTCOMES BY KEY PROGNOSTIC FACTORS IN EMERALD-1: A PHASE 3 STUDY OF DURVALUMAB ± BEVACIZUMAB WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PARTICIPANTS WITH EMBOLIZATIONELIGIBLE UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) | Publicación